Kisspeptin-10 is a short signaling peptide used in reproductive-neuroendocrinology and receptor-activation research. The original overview of this page asks three questions: KISS1-receptor signaling context, short-sequence assay design, and identity, purity, and content verification for the form actually purchased. Kisspeptin-10 is not interchangeable with kisspeptin-54.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
KISS1-receptor signaling context
Kotani and colleagues identified the product of the metastasis-suppressor gene KiSS-1, and shorter fragments they called kisspeptin-14 and kisspeptin-13, as endogenous ligands of the G-protein-coupled receptor GPR54 (also called AXOR12 or hOT7T175), and they reported that the peptides bind GPR54 with low-nanomolar affinities, stimulate phosphatidylinositol turnover, calcium mobilization, arachidonic-acid release, ERK1/2 and p38 MAP-kinase phosphorylation, and, in transfected Chinese hamster ovary cells, inhibit cell proliferation (Kotani et al., 2001). Their paper is a ligand-identity study. It should be read with the fragment-length language they used: kisspeptin-54 and shorter C-terminal fragments are related ligands, not a single catalog item.
Loss-of-function mutations in GPR54 were reported in people with hypogonadotropic hypogonadism, and mice lacking Gpr54 were described as having abnormal sexual development, establishing a published connection between this receptor and puberty (Seminara et al., 2003). That finding concerns receptor biology. It does not by itself specify which kisspeptin fragment is on a quotation.
Kisspeptin-10 in published models
Gottsch and colleagues reported that kisspeptin-10, administered in mice, stimulated LH secretion and induced Fos immunoreactivity in GnRH neurons (Gottsch et al., 2004). Thompson and colleagues reported that kisspeptin-10 stimulated the hypothalamic-pituitary-gonadal axis in male rats, including increases in plasma LH, FSH, and testosterone, with further hypothalamic, pituitary, and testicular findings in the designs they described (Thompson et al., 2004). Those are rodent-model observations for the decapeptide form.
Jayasena and colleagues reported a sexual dimorphism in gonadotropin responses to kisspeptin-10 in healthy adults. In men, serum LH and FSH rose after an intravenous bolus of kisspeptin-10 in the design they described. In women, the same paper reported no change in serum gonadotropins after intravenous bolus, subcutaneous bolus, or intravenous infusion of kisspeptin-10 during the follicular phase, whereas serum LH and FSH rose after an intravenous bolus during the preovulatory phase (Jayasena et al., 2011).
A later study in healthy men compared intravenous infusions of kisspeptin-10, kisspeptin-54, and GnRH. At the doses tested in that paper, kisspeptin-10 and kisspeptin-54 were associated with similar gonadotrophin secretion, while GnRH was more potent than either isoform (Jayasena et al., 2015). The authors noted that rodent work had suggested kisspeptin-54 was more potent than kisspeptin-10, which is one reason the two lengths should still be labeled as separate materials even when a particular human infusion design reports similar gonadotrophin responses. Those papers are published research observations. They are not a protocol, they do not provide administration or dosing guidance, and they do not describe a current catalog lot.
Identity, purity, and content verification
The brief should name the fragment (kisspeptin-10, not a generic “kisspeptin”) and match that name to the sequence, content, and lot on the report. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.
Kisspeptin-10 appears in Velnacor’s research-material catalog (internal product record, slug kisspeptin-10). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact fragment, specification, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.
Selected published literature
- Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, Brézillon S, Tyldesley R, Suarez-Huerta N, Vandeput F, Blanpain C, Schiffmann SN, Vassart G, Parmentier M. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry. 2001;276(37):34631-34636. doi:10.1074/jbc.M104847200. PubMed 11457843.
- Seminara SB, Messager S, Chatzidaki EE, Smith RR, Thresher AC, Acierno JS Jr, Shagoury JK, Al-Alam Y, Schwinof K, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O’Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 2003;349(17):1614-1627. doi:10.1056/NEJMoa035322. PubMed 14573733.
- Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, Seminara S, Clifton DK, Steiner RA. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145(9):4073-4077. doi:10.1210/en.2004-0431. PubMed 15217982.
- Thompson EL, Patterson M, Murphy KG, Smith KL, Dhillo WS, Todd JF, Ghatei MA, Bloom SR. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. Journal of Neuroendocrinology. 2004;16(10):850-858. doi:10.1111/j.1365-2826.2004.01240.x. PubMed 15500545.
- Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewska A, Vaal ML, Salkeld G, Patel S, Ghatei MA, Bloom SR, Dhillo WS. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. The Journal of Clinical Endocrinology & Metabolism. 2011;96(12):E1963-E1972. doi:10.1210/jc.2011-1408. PubMed 21976724. Cited as published clinical-research observations, not as a use instruction.
- Jayasena CN, Abbara A, Narayanaswamy S, Comninos AN, Ratnasabapathy R, Bassett P, Combes AJ, Kennedy S, Jiménez-Linan M, Frost C, Ghatei MA, Bloom SR, Dhillo WS. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction. 2015;30(8):1934-1941. doi:10.1093/humrep/dev143. PubMed 26089302. Cited as published clinical-research observations, not as a use instruction. Used here to keep kisspeptin-10 and kisspeptin-54 distinct.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.